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ABSTRACT 
This thesis work comprises the characterization of proteins from two different 
neuronal membrane receptor protein families: the growth factor receptor α-type of 
protein, growth arrest specific-1 (GAS1) and the leucine rich repeat transmembrane 
proteins, leucine-rich-repeat transmembrane-2, and synaptic adhesion-like molecules 
1 and 5. 
The GAS1 project has focused on the structural characterization of the recombinant 
human GAS1 protein, and on the possible interaction and effect of GAS1 on the 
tyrosine kinase receptor protein, re-arranged during transfection (RET), signalling. 
GAS1 has two different types of interactions, GAS1-RET signalling participates in 
neuronal survival and maintenance and GAS1-Patched1-Sonic hedgehog (SHH) 
signalling is needed both for cell survival and in the development of the enteric 
nervous system during early development. 
The study of leucine-rich-repeat transmembrane proteins (LRRTMs), and the synaptic 
adhesion-like molecules (SALMs) has concentrated on the production and 
characterization of an engineered variant of LRRTM2, SALM1 and SALM5. These 
proteins are involved in neurite outgrowth, branching and synapse formation. They 
are mainly expressed in brain, and their malfunction is connected to familial 
schizophrenia, bipolar disorder and autism. 
The goals of this thesis work were to produce these proteins, solve their structures, 
test their interactions with ligands and do functional characterization studies using a 
variety of methods. The results will contribute to a better understanding of the roles 
these proteins play in neuronal tissue and possibly generate new research into the 
cellular phenomena, including diseases,  linked to these proteins, and aid in future 
drug development. 
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1.?INTRODUCTION 
1.1? NEURONAL BIOLOGY BEHIND THE PROTEINS 
STUDIED 
Neuronal proteins can have different functions depending on the 
developmental stage of an individual. The nervous system is vulnerable already in 
early development; genetic mutations can severely affect the formation of the spinal 
cord, brain and the nerves of the intestine (Lee et al. 2000). Later on, in the aging 
individual, maintenance of the neural network requires supporting cellular signalling. 
Alterations in the cellular signalling patterns can cause cancers, or have effects on 
maintenance and formation of correct synaptic connections, possibly affecting the 
cognitive skills, or motor neurons of an individual (Kandel et al. 2000). 
In our bodies, in the central nervous system (CNS), all the motor, sensory and 
cognitive functions are controlled by neurons. The CNS in general is composed of 
neurons and several different types of glial cells, such as astrocytes, oligodendrocytes 
and microglia. The glial cells are crucial for maintenance of the nervous system by 
forming insulating myelination, providing nutrients and microglia for immunological 
effects (Kandel et al. 2000). However, all the information in the vertebrate nervous 
system goes through multipolar interneurons, motor neurons and sensory neurons. 
Morphologically all neurons have a nerve cell body, where several dendrites bring the 
signals from synapses, but only one axon takes the signal forward typically to another 
neuron (Figure 1), (Kandel et al. 2000).  
Basically, the signal moves forward electrically in the neural network, where the 
stimulus causes an action potential, i.e. an alteration in current. This transmission goes 
forward by the alteration of ionic strength inside the axon, and the potential is 
maintained, and ’amplified’ by charged ions, such as K+, Na+, and Ca2+ (Berridge 
2012). In the resting state, the ionic strengths are maintained by membrane proteins, 
such as voltage gated channels for Na+ or K+ -ions, and the Na+/K+ pump (Kandel et 
al. 2000). The signal can be transmitted from neuron to neuron by releasing 
Introduction 
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neurotransmitters from synaptic terminals into chemical synapses or by direct cell-cell 
contact at gap junctions in electrical synapses. 
The functionality of the CNS is complex and is maintained by many factors, such as 
receptors, adhesion molecules and neurotrophic factors, on the nerve cell body, axon, 
and synapses.  
In this thesis I have mainly focused on three different neuronal proteins: growth arrest 
specific 1 (GAS1), leucine rich transmembrane 2 (LRRTM2), and synaptic adhesion-
like molecule 1 (SALM1). GAS1 has been reported to have multiple functions, but all 
the proteins listed above have crucial basic functions in the formation of the vertebrate 
brain. For example, GAS1 supports the growth of the cerebellum in the embryo 
(Marques & Fan 2002; Lee & Fan 2001). LRRTM2 and SALM1 are required for 
formation of synaptic contact and maintenance in hippocampal regions (Homma et al. 
2009; Wang & Wenthold 2009). As a consequence of malfunction, or in combination 
with other factors, these proteins have been linked to various neuronal disorders, and 
their structures and functions are intensively studied. 
  
 
Figure 1: Schematic presentation of a neuron (modified from Ramon y Cajal (Llinás 2003; Kandel 
et al. 2000). Typically several dendrites (1) bring the signal to the cell body (2), where it goes forward 
by one single myelinated (yellow) axon (3) that carries the signal to presynaptic terminals (4), and 
from there to other cells, typically to another neuron (Südhof 2008).  
1
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1.2  NEURONAL DISORDERS - RELATION TO THE 
INVESTIGATED MOLECULES AND TREATMENT 
 One of the interesting aspects of the molecules studied is that GAS1 has 
been linked to Parkinson’s and Hirsprung’s disease via its interaction with RET (Zarco 
et al. 2012; Cabrera et al. 2006), whereas LRRTM2, and SALM1, have been 
associated with the autism spectrum of disorders, bipolar disorder and familial 
schizophrenia (Seabold et al. 2008).  
All of the listed neuronal disorders have been well studied, and their typical symptoms 
are fairly well known, mainly their cognitive effects. However, the different factors 
causing the malfunction on the cellular level are only partly understood. The cellular 
signalling patterns and interactions are complex, and for this type of disease typically 
several genes have a joint effect on the particular function in neurons.  
Structures of GAS1, LRRTM2 and SALM1 would reveal the characteristic 
biophysical features of these proteins, and enable us to better understand the possible 
ligand receptor interactions and the links to the disorders. The levels of the disease 
symptoms may vary between individuals, and even though some drugs are available, 
for example for Parkinson’s disease and schizophrenia, they have a high number of 
side effects due to their off-target impacts (Kandel et al. 2000; Aron & Klein 2011). 
An interesting example of the off-target effect is that traditional drugs used to treat 
schizophrenia, actually created Parkinson-like symptom in patients, most likely by 
affecting the function of dopaminergic neurons (Seeman et al. 1976). On the other 
hand drugs used to treat Parkinson’s, might cause behavioural changes, i.e. addictions, 
such as gambling, hyper sexuality, and compulsory shopping (Dagher & Robbins 
2009). One interesting aspect pointed out by Johnson (2015), was that many pre-
clinical trials on age-related neurodegenerative disorders, such as Parkinson’s disease, 
were done in the immature nervous system of rodents, which in fact does not 
correspond to the real situation in aging human patients, and might reflect the 
problems with the therapeutic agents available (Johnson 2015). 
Research in recent years has brought more understanding and focus on different 
neuronal disorders in which genetic factors cause cognitive dysfunctions, such as 
autism spectrum disorders, familial schizophrenia, and bipolar disorder. Typical for 
Introduction 
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these types of cognitive disorders is that they have been reported to have high 
heritability, and even though they are considered as different psychiatric disorders, 
they share similar behavioural, and cognitive effects; it has been hypothesized that 
some share the same genetic alterations (Carroll & Owen 2009).  In familial 
schizophrenia the genes underlying the dysfunction are most likely active before the 
symptoms appear, and the physiological changes start years before the cognitive 
effect. 
 Currently, much research is focused on synaptic cell adhesion molecules, and proteins 
interacting with them, as they are considered to be one of the key factors behind these 
types of heritable disorders (Carroll & Owen 2009). As mentioned, the symptoms that 
develop are caused by the joint impact of several genes, and the medication is 
challenging. Schizophrenia and bipolar disorder both have mood alterations from 
manic behaviour to depression, whereas schizophrenia can lead to more drastic 
symptoms, such as hallucinations, altered sense of environment and personality, face 
recognition, and psychotic behaviour (Kandel et al. 2000). On the other hand the 
debilitating Parkinson’s disease is known mainly for effects on mobility and tremor, 
which are thought to be caused mainly by the degeneration of dopaminergic neurons 
in the substantia nigra (Aron & Klein 2011). But Parkinson’s disease can also cause 
other symptoms such as  depression and dementia. 
Based on the level of the cognitive symptoms, the mentioned disorders cause 
challenges throughout the patient’s life, affecting their welfare and their integration 
into society. Overall, there is now an increasing need to understand the neuronal 
disorders better. Since the average lifespan of humans is increasing, the occurrence of 
neurodegenerative diseases in aging individuals, such as the most common disorders, 
will become more frequent (Aron & Klein 2011). Roughly 44 million people in 2016 
have been reported to have the most common neurodegenerative disorder, 
Alzheimer’s disease  (alz.org), and 6.3 million have Parkinson’s disease (European 
Parkinson’s disease association, (epda.eu.com). In fact, Parkinson’s is the second most 
common neurodegenerative disorder, affecting around 1 % of people over 60-years 
old (Reeve et al. 2014). In addition approximately 1.1 % of the U.S. population has 
schizophrenia (nimh.nih.gov, 2016)  
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Knowledge gained from the study of these disorders, can be combined with knowledge 
on neuronal disorders with cognitive effects in general, such as autism spectrum 
disorders and Asperger’s syndrome. Approximately 1% of the world population has 
an autism spectrum disorder (autism-society.org), and possibly one out of 250 people 
has Asperger’s syndrome (aane.org).
1.3 GAS1 AND ITS INTERACTIONS  
The survival of neuronal cells is dependent on correct signalling, and factors 
supporting neuronal survival, i.e. neurotrophic factors (Evans & Barker 2008). GAS1 
is one of the neuronal co-receptor proteins, widely expressed in the central nervous 
system (Zarco et al. 2012). It was originally discovered as a growth arrest protein, able 
to stop the cell cycle in S-phase, and possibly to prevent cancer progression (Del Sal 
et al. 1992; Schneider et al. 1988; Lee et al. 2001) in a p53-dependent manner (Del 
Sal et al. 1995; Derry et al. 2001) (Figure 2).  
 
 
Figure 2: GAS1 is expressed in growth arrest. GAS1 is able to stop the cell cycle progression to 
DNA-replication, the synthesis S-phase. 
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The gene encoding the GAS1 protein does not have introns, indicating possibly that it 
has a retrotransposon origin (Zarco et al. 2012). GAS1 has been considered to be an 
ancestral protein, which diverged early in evolution from a common origin with the 
homologous co-receptor GFRα-proteins (Hätinen et al. 2007; Airaksinen et al. 2006). 
Recently, GAS1 was discovered to be involved in two different types of signalling 
pathways, in a transmembrane tyrosine kinase pathway involving RET (López-
Ramírez et al. 2008; Cabrera et al. 2006), and in hedgehog signalling (Allen et al. 
2007; Martinelli & Fan 2007a). In hedgehog signalling, GAS1 has been reported to 
interact with Sonic Hedgehog (SHH), other Hedgehogs, such as Indian Hedgehog 
(McLellan et al. 2008). GAS1 might alter the signalling of SHH directly through the 
membrane protein Patched1, or possibly with Smoothened receptor (Smo) (Seppala et 
al. 2007; Martinelli & Fan 2007b). How the concentration dependent action of soluble 
SHH occurs through the Smo-Patched interaction is unknown (Briscoe et al. 2001). In 
addition, due to its growth arrest ability, GAS1 is considered to be a important factor 
preventing tumours (Evdokiou & Cowled 1998; Mellstrom et al. 2002), and may 
possibly prevent glial cell derived tumours (Zamoraro, 2004, Benitez 2007, 
Dominques-Monzon 2009). The ability of GAS1 to arrest growth has been studied 
extensively because of the possible clinical applications, such as preventing the 
formation and migration of gliomas, brain tumours that originate in glial cells (López-
Ornelas et al. 2014). Gliomas are the most common lethal brain tumours; they are 
highly invasive and have a tendency to create satellite tumours. Presently, there are 
very few therapeutic approaches available against gliomas, and this cancer type has a 
very poor prognosis (López-Ornelas et al. 2014). 
Structurally, based on sequence conservation, GAS1 is predicted to be a distant 
homolog to Growth factor receptor alpha group members (GFRαs). The sequence 
conservation is low, being highest for GAS1 compared to GRFα1 (28 %) (Schueler-
Furman et al. 2006). Based on conserved residues, mostly cysteines, GAS1 is 
predicted to be a two domain, cysteine rich, mostly α-helical protein, which has one 
N-glycosylation site at Asn117, and is membrane bound by its 
glycosylphosphatidylinositol (GPI)-anchor (Figure 3) (Stebel et al. 2000; Ruaro et al. 
2000). The N-glycan is considered to be important in vertebrate GAS1-SHH 
interaction (Martinelli & Fan 2007a). 
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The predicted homologous proteins, GFRαs, are a four membered co-receptor group 
GFRα1-4, which are able to bind specific glial cell-line derived neurotrophic factors, 
GDNF family ligands (GFL) (Saarma 2000). There are four cysteine knot structured 
GFLs which belong to the transforming growth factor (TGFβ) superfamily 
(Airaksinen et al. 1999): Glial cell derived neurotrophic factor (GDNF), Neurturin 
(NRTN), Artemin (ARTN), and Persephin (PSPN), (Kotzbauer et al. 1996; Milbrandt 
et al. 1998; Baloh et al. 1998; Sariola & Saarma 2003). Of these, GDNF and NRTN 
have co-receptors expressed in the CNS, where as ARTN and PSPN are active in the 
periphery (Honma et al. 2002). Mainly these proteins are considered to have favoured 
ligand-co-receptor pairs, but crosstalk between different GFL-GFRα pairs has been 
reported (Figure 3) (Airaksinen & Saarma 2002).  
The signalling pattern is complex; GFLs are cysteine rich, dimeric ligands, which are 
able to bind two GFRα co-receptors. The formation of the dimeric GFRα-GFL 
complex enables the association with two RET receptors (Kjær & Ibáñez 2003a; 
Mason 2000; Leppänen et al. 2004; Virtanen et al. 2005). Functionally RET is a 
transmembrane kinase protein (Takahashi & Cooper 1987). Structurally, RET has four 
extracellular cadherin like domains (Nollet et al. 2000), a cysteine-rich domain, a 
Ca2+binding site, a single transmembrane helix and a C-terminal kinase domain 
(Anders et al. 2001). The Ca2+binding site has importance in ligand binding, and the 
RET complex formation with GFRα-GFL enables the phosphorylation of the 
intracellular tyrosine residues of RET. Due to the altered phosphorylation, RET further 
activates intracellular signalling molecules, and this changes the intracellular 
signalling. 
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Figure 3: GAS1, RET, GFRαs1-4, GDNF family ligands (GFL). There are four GFLs (lilac); Glial 
cell derived neurotrophic factor (GDNF), Neurturin (NRTN), Artemin (ARTN), and Persephin (PSPN), 
which have four corresponding receptors GFRα (1-4) (blue). As a complex they are able to bind to the 
transmembrane kinase RET (green), which comprises a Ca2+ binding site (orange), cysteine-rich region 
(yellow),transmembrane region (blue), and intracellular kinase domain (blue line with red stars), which 
causes phosphorylation and triggers the intracellular signalling (Sariola & Saarma 2003). The role of 
GAS1 (left, blue) is not clear. Approximate position of the predicted glycan is marked (orange line). 
 
In the brain, RET is expressed in the substantia nigra of adult midbrain dopaminergic 
neurons (Trupp et al. 1998; Lin et al. 1993), and RET signalling has been considered 
to be important in neuronal survival and maintenance.  RET’s interaction with GDNF 
most likely supports the survival of dopaminergic neurons in Parkinson’s disease but 
the mechanism is unclear (Yu et al. 2008). Interestingly a leucine rich repeat protein, 
Lrig, which is induced by the effect of GDNF, has been suspected to regulate the 
activity of RET by inhibiting GDNF binding (Ledda et al. 2008). The ability of GAS1 
to inhibit glioma growth has been considered to occur through inhibition of the effect 
of GDNF (López-Ramírez et al. 2008; Zarco et al. 2012).  
?
RET
GFR?
GFL
GAS1
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RET is an important drug target as it is a proto-oncogene (Santoro et al. 2004), and  
the overactivity of RET, for example caused by variable genetic mutations, can cause 
certain types of thyroid cancers  (Grieco et al. 1990; Donis-Keller et al. 1993; Mulligan 
et al. 1993; Hofstra et al. 1994). The lack of RET kinase function causes Hirsprung’s 
disease (Pelet et al. 1998; Geneste et al. 1999; Kjær & Ibáñez 2003b). In Hirsprung’s 
disease the altered RET signalling causes a severe lack of nerve bodies in the colon, 
inhibiting colon function, and phenotypically causing the formation of a mega colon 
already in new-born infants (Jin et al. 2015). The RET gene is probably prone to 
mutations as it is alternatively spliced to three different isoforms, 51, 43, and 9 
(Richardson et al. 2012), and their main structural difference is that the variants have 
non-identical C-terminal domains, which results in different types of phosphorylation 
patterns (Songyang et al. 1995). 
However, more structural and functional data are needed, as the function of GAS1 in 
RET signalling is unclear. In addition, RET structure and signalling overall still 
requires further clarification (Ibáñez 2013).  
One clinical approach to a possible future treatment for Parkinson’s, would be to 
deliver recombinant GDNF to the brain (Bespalov & Saarma 2007; Gill et al. 2003). 
However, the protein would have to cross the blood-brain barrier, and the delivery of 
recombinant GDNF directly to brain might cause inflammation (Lang et al. 2006). 
Direct delivery of GDNF and NRTN to rat brains has been tested, but to gain positive 
effects on dopaminergic neurons, and prevent negative effects caused by wider 
distribution of GFL, advanced knowledge of pharmacokinetics is needed to determine 
the dose levels, frequency of delivery, and delivery methods (Gill et al. 2003; 
Hadaczek et al. 2010). The effect of RET in dopaminergic neurons has been argued, 
and the existence of an alternative receptor for GDNF has been suggested (Pozas & 
Ibáñez 2005).  Furthermore, GDNF has been reported to promote synaptogenesis in 
hippocampal neurons with GFRα1 (Paratcha & Ledda 2008), and to interact with 
receptors other than RET, such as neural cell adhesion molecule (NCAM) (Paratcha 
et al. 2003; Kallijärvi et al. 2012), and syndecan-3 (Bespalov et al. 2011). Thus other 
molecules than GDNF-family ligands could be important in regulation of RET 
activity. Since GAS1 has been found to bind RET in a ligand independent way 
(Cabrera et al. 2006), this may increase the value of GAS1 as an alternative drug target. 
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Furthermore, GAS1 is involved in the sonic hedgehog (SHH) signalling pathway, 
which is very important in stem cell survival, embryonic patterning (Lee & Fan 2001), 
and growth of the cerebellum (Del Sal et al. 1992; Cabrera et al. 2006). Increased 
expression of GAS1 associated with neuronal cell death is found in early development 
(Mellstrom et al. 2002). The hedgehog proteins actively participate in cell survival 
throughout life, from early development onwards. One of the critical phases in GAS1-
SHH interaction is, in fact, considered to occur in early development (Allen et al. 
2007; Martinelli & Fan 2007a). Failure in GAS1-Patched1-SHH, and possibly 
smoothened (Smo), interactions causes severe cranio-facial malformation (Pineda-
Alvarez et al. 2012; Ribeiro et al. 2010; Martinelli & Fan 2007b), such as cyclopia, 
and here the lack of SHH signalling is mostly lethal. Both Patched1 and Smo are 
transmembrane proteins, which participate in SHH signalling, but how the interaction 
occurs between GAS1-Patched1-Smo, is not yet defined (Figure 4).  
??
 
Figure 4: GAS1 signalling complexes. (A) GAS1-SHH-Patched1 (B) and with Smo (C) interaction. 
(A) From right: The RET cadherin domain (green), containing a Ca2+binding site (red dot), and 
transmembrane domain (blue line with red stars). The activation of RETs intracellular region (orange 
lightings). GPI linked GFRαs (blue), as a complex with GFL (lilac). On the left: GAS1 (blue) and GFL 
(lilac). GAS1 role in this interaction is undefined. (B) Transmembrane protein Patched1 (blue tiles), 
SHH (lilac), GPI-linked GAS1 (blue) complex Smo (orange) and BOC/CDO (yellow with red lines). 
With GAS1-Patched1-SHH-BOC/CDO interaction possibly repress Smo (Pan et al. 2013). C) GAS1 
(blue), Patched1 (blue tiles), SHH (lilac). GAS1s may interact with SHH-Patched1, without Smo. The 
small line in GAS1 domain1 indicates the glycosylation site (orange). The orientation of the glycan in 
the interaction is unknown, and placed here only to indicate the approximate position in the first domain. 
B
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Considering the structural data, there are several crystal structures of Hedgehog 
proteins available, for example the sonic hedgehog-heparin complex structure (PDB 
4C4N).  
However, for GAS1 and RET there are no crystal structures available, and the mode 
of interaction is not clear. The GRFα1-GDNF (PDB 3FUB) (Parkash & Goldman 
2009) and GFRα3-Artemin structures (PDB 2GH0) (Wang et al. 2006) are published, 
and a partial electron microscopy-SAXS combination structure of RETs extracellular 
cadherin domains was recently solved (PDB 4UX8) (Goodman et al. 2014). 
Interestingly, GFRα1, 2 and 3 are predicted to have three domains, whereas GAS1 
and GFRα4 have only two (Airaksinen & Saarma 2002). However, none of the three 
domained structures are available on GFRαs (Scott & Ibanez 2001), and the solved 
structures are all lacking the predicted first domain. 
 
1.4 SALMS, LRRTMS AND SYNAPTIC ADHESION 
In addition to the survival of the neuronal cells one of the important factors in 
the correct function of the brain is the formation and maintenance of synaptic contacts 
between neurons, and maintenance of the plasticity of brain. The formation of synaptic 
connections involves cell adhesion molecules (CAM) and recently, several LRR 
adhesion proteins have been discovered and studied intensively, as they have been 
shown to participate in driving the synaptic adhesion, and to be able to form new 
synaptic connections (Ko & Kim 2007). According to Südhof (2008) the synaptic 
connections form most likely in a three stepped process, involving the recognition of 
the target cell, formation of contacts of synaptic components, and finally maturation 
of the connection. LRR proteins are considered to be important factors in the 
organization and correct patterning of the nervous system, and maturation of chemical 
synapses (Südhof 2008; de Wit & Ghosh 2014). The imbalance of inhibitory and 
excitatory synaptic contacts is considered to underlie cognitive neuronal diseases 
(Südhof 2008; Woo et al. 2009; Linhoff et al. 2009). 
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LRRs are a very large group, named after their typical pattern of repeating leucine rich 
regions, that form a curved structure capped by cysteine rich domains at both N- and 
C-termini (Kobe & Deisenhofer 1995; Kajava 1998). The four membered protein 
family (LRRTM1-4) (Laurén et al. 2003) (Figure 5) seem to have emerged during the 
evolution of chordates (Uvarov et al. 2014), and of these the neuronal LRR-proteins 
most likely have evolved due to the complex regulation of synaptic functions needed 
in the vertebrate nervous system (Laurén et al. 2003; de Wit & Ghosh 2014). 
 
 
 
Figure 5: LRRTM (1-4) proteins. Proteins share similar extracellular domains, with ten LRR repeats
(oval, bue), capping domains in N- and C-termini of the LRR domain (yellow box), single 
transmembrane part (TM), short cytoplasmic tail withpost-synaptic density (PDZ) binding-motif (Ko 
2012; Laurén et al. 2003). Both LRRTM3 and 4 have two splice variants. The isoforms have either a 
shorter ca 72 amino acids or longer ca. 140 amino acids cytoplasmic tail (see for example UniProt 
entries human Q86VH5 and Q86VH4). 
 
In my thesis, I have focused mostly on the neuronal leucine rich transmembrane 
protein 2 (LRRTM2), and synaptic like adhesion molecule 1 (SALM1) (Figure 6). 
Cytoplasmic                            
PDZ-motif  (LRRTM1-4)
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C-cap         C
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Figure 6: Examples of extracellular LRR proteins and the LRR domain. From left: LRR domain 
structure of NetrinG2 represents a typical curved LRR domain with capping regions, followed by an Ig 
C2 domain Pymol (Schroedinger) figure, model based on solved X-ray structure 3ZYI (Seiradake et al. 
2011). Schematic presentations of SALM1 (middle) and LRRTM2 (right) proteins. The blue arrow 
passes through the LRR domain, SALM1 having seven, and LRRTM2 ten repeats (blue oval figures) 
Capping domains (yellow boxes). SALM1 has also an IgC2 type domain after the LRR domain (green 
box) and fibronection domain (blue box). The predicted glycosylation sites on SALM1 (Uniprot, entry 
code Q9ULH4) and LRRTM2 (Uniprot, entry code O43300) proteins are indicated (orange.)  
The extracellular domains of LRRTMs have been shown to be ligands of neurexins 
(NRXNs) and form synaptic adhesion complexes by binding to these presynaptic 
proteins (de Wit et al. 2009; Ko et al. 2009); LRRTM4 also bind to glypicans (DeWit 
et al. 2013; Siddiqui et al. 2013). Netrin G-ligands form a similar type of leucine rich 
protein family (for structure see PDB 3ZYI, Figure 6). 
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Neurexins are neuronal cell adhesion molecules, which are expressed in presynaptic 
sites and have at least five alternative splice variants (Treutlein et al. 2014). Neurexin 
domains are composed of laminin-neurexin-sexhormone (LNS) and epidermal growth 
factor like (EGF) domains (Koehnke et al. 2008; Reissner et al. 2013; Schreiner et al. 
2014; Siddiqui et al. 2010) (Figure 7). They are expressed in two different forms, α- 
and β-NRXN. The interaction of neurexins with neuroligins has been linked to genetic 
autism in humans (Zhang et al. 2015). 
 
 
 
Figure 7: Neurexin structure and splice sites. From top left: the longer form precursor protein α-
neurexin, and the shorter β-neurexin. The oval (white) shapes represent laminin-neurexin-sex 
hormone binding globulin domains, and the circles  (green) are epidermal growth factor domains. 
Right: membrane (yellow), the intracellular tails are identical (blue). Neurexins have five splice sites, 
which enable alternative splicing that yields several different isoforms (red lines). Figure modified 
from (Koehnke et al. 2008). The β-neurexin  and α-neurexin X-ray structures have been solved 
(Tanaka et al. 2012; Reissner et al. 2008; Koehnke et al. 2008; Araç et al. 2007; Fabrichny et al. 
2007). Example structure of β-neurexin (right, green). Model from PDB 3BIW (Araç et al. 2007), 
using Pymol (Schroedinger). 
LNS domains
EGF domains
Splice site
?-NRX
β-NRX
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NRXNs are expressed in various brain regions and have several different ligands (Woo 
et al. 2009), including neurexophilin, neuroligin (Araç et al. 2007), dystroglycan, 
GABA(A)R, LRRTMs and cerebellin (Reissner et al. 2013).  
While LRRTMs form complexes with ligands, thus far SALMs are considered to form 
mainly homo- or heteromeric connections to other SALM proteins. SALMs form a 
five membered group (SALM1-5) (Nam et al. 2011; Mah et al. 2010), which seem to 
share similar extracellular structure with LRR, Immunoglobulin C2, and Fibronectin 
III domains, but have variable cytoplasmic C-terminal tails (Nam et al. 2011) (Figure 
6). SALMs are expressed mainly in brain, and only in vertebrates. They are 
glycosylated, for example the SALM1 extracellular domain has four predicted 
glycosylation sites (Asn29, 332, 341, 384), and the average molecular weight of 
SALMs is higher than predicted due to glycosylation (Figure 8). In SALM1-3, the C-
terminal tail has a (PDZ) binding domain motif (Seabold et al. 2008). PDZ domain is 
typically interacting with post synaptic density (PSD95) family of proteins, such as 
Post synaptic density (PSD95), Drosophila disc large tumor suppressor (Dlg1), and 
zonula occludens-1 (ZO1). PSD95 is involved in correct membrane location and 
targeted trafficking in neurons (Seabold et al. 2012). Deletion of the C-terminal 
domain from a SALM1 construct has been shown to prevent axonal growth, possibly 
due to incorrect export from the ER (Wang & Wenthold 2009). 
SALM1-3 have mainly been reported to form homo-and heteromeric contacts 
(Seabold et al. 2008). However, recently some ligands for SALMs have been found. 
SALM3 was reported to interact with the presynaptic protein tyrosine phosphatase 
PTPRσ (PTPRsigma), and has its main effect on the brain locomotive area (Li et al. 
2015). SALM5 interacts with LAR (leucocyte common antigen related) (Zhu et al. 
2016). LAR and PTPRσ both belong to the family of receptor protein tyrosine 
phosphatases that have  regulatory functions in axons and dendrites (Zhu et al. 2016).  
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Figure 8: The SALM1-5 extracellular domains. From left: seven LRR repeats (blue ovals), capping 
domains in C-and N-termini (yellow boxes), IgC2-type (green), and fibronectin III type domains (light 
blue). On the right: short transmembrane part (orange line), and cytoplasmic C-terminal tail (blue line). 
The length and sequence of the C-terminal tail varies from SALM4 with 66 amino acids to SALM1 
with 233 amino acids (AA). SALM1-3 has a PDZ-binding motif in the intracellular C-terminal tail 
(black line). In general, the molecular weight of SALMs is roughly 20 kDa higher than predicted due 
to heavy glycosylation. Predicted glycosylation on mouse SALM proteins is marked with figures as 
described (left), with the corresponding amino acids listed. There is some variation in domain 
boundaries, and the predicted glycans are positioned approximately to represent the typical sites and 
pattern in comparison to other SALMs. Reference sequences are listed in Uniprot with entry codes 
mouse SALM1 (Q80TG9), SALM2 (Q2WF71), SALM3 (Q80XU8), SALM4 (Q8BLY3), SALM5 
(Q8BXA0) 
 
This study of the neuronal LRR-proteins focused mostly on analysis of the effect of 
protein engineering on LRRTM2 and SALM1 expression, stability, and 
crystallizability. Both LRRTM2 and SALM1 were tested for ligand binding, 
LRRTM2 for neurixin binding ability, and SALM1 was used to screen for potential 
ligands.  
N CIgC2 FNIIIC
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 27 
Both LRRTM2 and SALM1 are predicted to localize mainly to dendritic spines, 
whereas the deletion of the C-terminal domain allowed the expression of both proteins 
to broaden to axons and dendrites (Seabold et al. 2012), which possibly indicates 
incorrect localization and shows the importance of the PDZ binding domain already 
at the  ER level. The incorrect localization of SALMs and LRRTMs has been 
suspected to cause impairment, and possibly underlie neuronal diseases (de Bruijn et 
al. 2010; Wang & Wenthold 2009; Xu et al. 2009). Synaptic connections are complex, 
and the same subset of molecular alterations can cause different forms of cognitive 
effects, i.e. the type of disorder. Since the synaptic connections and neural circuit 
specify the functionality, the disorder might be misdiagnosed (Südhof 2008). 
 
1.5 PRODUCTION AND CRYSTALLIZATION OF NEURONAL 
AND OTHER CHALLENGING PROTEINS 
A typical bottleneck in structural biology is the crystallization of the 
proteins. Even when the protein does not have flexible, or disordered parts, several 
unknown variables can affect the crystallizability. The problem with initial sparse 
matrix crystallization screens is that one cannot predict the effect of the various 
chemicals on the studied protein. The optimization is not easy, and in order to create 
the optimal conditions for crystallization trials, the best option would be to obtain a 
large amount of functional protein, preferably from the same batch. When considering 
the amounts of proteins produced in a typical academic research lab, it is very 
challenging to produce sufficient quantities of neuronal proteins, which have 
disulphide bridges that potentially complicate the folding processes and post-
translational modifications such as glycosylation.  
The production methods are costly if using insect cell or mammalian cell culture 
production systems. Alternative methods for production, such as using E. coli should 
be considered, when possible. If the protein does not crystallize, modification of the 
construct is needed. Either this can be done by optimizing the construct by mutations 
(Study II), by doing limited proteolysis to cleave of the flexible parts (Study I, data 
not shown) or by redesigning the construct, for example by producing domains 
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separately (Study I) or by engineering the construct to crystallisable form (Study II). 
The obtained crystals can diffract poorly due to insufficient cryo-conditions or poor 
organization of crystal lattice. Naturally the optimization of cryo-conditions is 
crucial, but might not be sufficient in order to gain high quality data. The packing 
and thus the orderedness of the crystals can be one of the bottlenecks and may be 
improved also during data collection by doing cryo- annealing and crystal 
dehydration (Study III) (Process, Figure 9). 
 
?  
 
 
Figure 9: Crystallization trials. The process can stop in each step. Green arrows indicate the 
optimal process. If optimization does not lead to diffraction, and structure, or sparse 
matrix/optimization screens do not give any results, the project might have to be restarted by 
construct optimization and recloning (red arrow between sparse matrix screen, optimization 
screen, construct optimization and recloning). Possibly the organization of lattices in crystals 
is poor, and optimization of crystallization does not lead to structure, and the project needs to 
be restarted (Red arrow pointing back to construct optimization and sparse matrix). 
Sparse matrix screen
Optimization of the cryo-conditions
Diffraction and structure
Optimization screen
Construct optimization and recloning
 29 
2.?AIMS OF THE PRESENT STUDY 
The aims of the study were the structural and biophysical characterization of neuronal 
proteins: GAS1, LRRTM2, SALM1 and SALMs. The specific goals were:  
 
1.? To produce recombinant human GAS1 protein for crystallization using baculovirus 
expression, and to use the purified protein for biophysical characterization studies. To 
solve the solution and crystal structures of GAS1, to test RET binding and to determine 
how GAS1 is able to bind several ligands. 
2.? To produce an engineered, recombinant mouse LRRTM2 protein for crystallization, 
to characterize the protein biophysically and to test the modified protein’s ability to 
bind NRXN in vitro. 
3.? To produce recombinant mouse SALM1 and SALM5 proteins in Drosophila S2 cells, 
to characterize the proteins using biophysical methods and X-ray crystallography to 
investigate the structure, and to find new ligands against recombinant SALM1 from 
brain samples. 
 
These contructs were chosen for the initial structural studies to give an overall basis 
for further studies, not to be used for pre-clinical trials. For LRR proteins we had 
mouse cDNA available, which is almost identical in amino acid sequence to human 
protein. These mouse constructs could be used to do basic research for demanding 
neuronal target proteins. Based on, and beyond this thesis work, the corresponding 
human recombinant proteins would be more suitable for disease models, and the 
findings would better support future pre-clinical trials. 
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3.?MATERIALS AND METHODS 
The proteins were subcloned into suitable protein production vectors, and produced 
for biophysical, biochemical, and structural studies. Several methods were used and 
they are listed here in Table 1.  
All the materials, and methods used in this thesis are described in detail in the original 
publications. An unpublished study is described in section 3.1. 
Table 1: Methods used in this study 
Method Used in this study 
PCR I, II, III 
DNA sequencing I, II, III 
Cloning I, II, III 
Baculovirus production and purification I, II 
Drosophila S2 production and purification III 
Western blotting I, II, III 
Sequence alignments I, II, III 
Sequence based construct modifications I, II, III 
Circular Dichroism  I, II 
Thermofluor assay I, II, III 
Multi Angle Laser Light Scattering I, II, III 
Small Angle X-ray Scattering I, II 
Homology modelling I, II, III 
Surface plasmon resonance I, II, III 
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X-ray crystallography I, II, III 
Pulldown for MS analysis  (III) 
 
3.1 PULLDOWN ASSAYS AND MASS SPECTROSCOPY 
Extracellular, recombinant SALM1-Fc (amino acid residues 20-378), 
LRRTM2-Fc (amino acid residues 30-421), and plain purified Fc-tag control were 
used as bait in a ligand screening. The baits were prepared by incubating the Fc-tagged 
proteins on protein A beads (GE Healthcare, USA) in a batch column, overnight at + 
10 oC.  
In brief, membrane extract from 25 rat brains was used as a ligand source. Extract was 
incubated overnight with the beadbound Fc-tagged proteins (Savas et al. 2014). On 
the following day the mixture was washed, and Fc-tagged ligand complexes were 
eluted from columns. Protein sample were prepared for mass spectrometry (MS) 
analysis, and used for MALDI-TOF (Viikki proteomics unit). 
A detailed protocol for the pull-down assay and preparation of samples for MS-
analysis can be found in Savas, Jeffrey, et al., ‘Ecto-FC MS identifies ligand receptor 
interaction.’ (Savas et al. 2014). Pulldown and MS-analysis were done in collaboration 
with the group of Prof. Matti Airaksinen at the Neuroscience Center and Institute of 
Biomedicine, Faculty of Medicine. 
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4.? RESULTS AND DISCUSSION 
 4.1 BIOPHYSICAL CHARACTERIZATION 
The proteins were biophysically characterized using Thermofluor™ assays (Study 
II, III), circular dichroism (CD) (Study I, II), and differential scanning calorimetry 
(data not shown). The oligomerization status of the proteins was estimated by size 
exclusion multi-angle laser light scattering (SEC-MALLS), and their overall solution 
structure was obtained by using solution X-ray scattering (SAXS). I aimed to obtain 
crystals from proteins, GAS1 and SALM1 (Studies I, III) and solve the structures by 
X-ray crystallography. We analysed the receptor ligand interactions by surface 
plasmon resonance (Studies I, II) or ELISA-binding assays (unpublished). Supporting 
cell based assays to test the interaction were performed for GAS1 (unpublished). A 
pulldown assay for ligand screening by MS was done for SALM1 (unpublished data 
from Stydy III). 
4.2? GAS1 (STUDY I) 
4.2.1? GAS1 PRODUCTION BY BACULOVIRUS METHOD AND RET BINDING 
The soluble recombinant GAS1 protein construct was produced without a GPI-
anchor using the baculovirus expression system (details in Study I) (Figure 10).  
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Figure 10: GAS1 production using a baculovirus method. A) The extracellular part of GAS1 (AA40-
318), His-tag, and thrombin (THR) cleavage sites were cloned to a baculovirus vector (Keinanen et al. 
1998), containing a secretion signal and FLAG-tag. The virus was expressed in Sf9 cells, and produced 
in Tricoplusia Ni-cells. B) Purified, untagged approximately 40 kDa GAS1 protein was separated on 
an SDS-page gel. Adapted from Study I, (Rosti et al. 2015), reproduced with permission from BMC 
Biochemistry. Copyright (2015) www.biomedcentral.com. 
 
The ability of GAS1 to bind the extracellular part of RET without a GFL ligand  was 
studied by surface plasmon resonance. The affinity of GAS1 for RET was found to be 
significantly lower (ca. 12 μM) that that reported for other homologous receptor
proteins, e.g., GFRα, in complex with a ligand to RET. The interaction between GAS1 
and RET was micromolar compared to nanomolar for GFRα1-GDNF (Kjær & Ibáñez 
2003a; Trupp et al. 1996). Also GPI anchored GFRαs are reported to be able to bind
to RET, without GFLs (Trupp et al. 1998). 
The affinity obtained is only an indication that such an interaction occurs, and supports 
the findings (Cabrera et al. 2006) that GAS1 can bind RET in a ligand independent 
manner. An attempt was made to develop an ELISA method to test the possible 
interactions with GAS1 to GFLs (GFLs were a kind gift from Prof. Saarma). The idea 
was to estimate the possible complex formation by binding GFLs to an ELISA plate, 
and detecting the FLAG-tagged GAS1 ligand. However, FLAG-tagged GAS1 had a 
pK509.3 baculovirus vectorAA    40- 318
SECRETION FLAG HIS THR GAS 40-318
????
100
70
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high affinity for all the tested ELISA plates, and consistently gave a false positive 
signal (data not shown). Due to the limited amount of GAS1 and GFL ligands high 
throughput screening was not possible. Based on our other results, the GAS1-GFL 
interaction is not favourable. 
Our sequence and structure modelling analyses indicate that GAS1 lacks the amino 
acids reported for interaction in GFRα-GFL ligand binding. The possible inhibitory 
effect of GAS1 on RET phosphorylation by cell based assays was tested but no clear 
inhibition was detected (Leppänen and Saarma, unpublished data). Our SAXS model, 
in combination with homology modelling indicates that most likely GAS1 has a 
domain structure similar to that of GFRα. However, unlike GFRα, GAS1 has a large 
flexible loop region in domain 1, lacks the GFL binding residues, and does not have 
affinity for heparin. These findings suggest that GAS1 differs significantly in function 
from GFRαs. 
One can hypothesize that the high expression levels of GAS1 might enhance binding 
to RET, even with low affinity. In addition, the affinity to RET might be higher if 
GAS1 is bound to an as yet unknown ligand. Its affinity for RET might be increased 
when the protein is GPI anchored to the membrane. Therefore, GAS1 might have a 
different effect on RET function when it is soluble, compared to the GPI anchored 
intact protein. Recently there was a supporting finding by López-Ornelas that soluble 
GAS1 can arrest the formation of gliomas by possibly inhibiting GDNF signalling 
(Lopez-Ornelas et al. 2011; López-Ornelas et al. 2014)  (Figure 11). 
??
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Figure 11: GAS1 soluble or GPI-anchored. GAS1 attached to the membrane by a GPI-anchor might 
have different properties than the soluble protein. Hypothetical soluble domains separated by red line. 
Predicted glycan is marked to domain 1 with line (orange). The role of the glycan in the interaction is 
not known. Ca2+ is considered to be important in RET-ligand (GDNF) binding (Anders et al. 2001). 
 
In another experiment that was carried out to detect the potential GAS1-SHH 
interaction the recombinant SHH N-terminal domain (AA 40-194), for structure see 
for example (Pepinsky et al. 2000) PDB 3MIN,  was cloned and purified as an GST-
fusion protein from E.coli to be tested for GAS1 binding in SPR. However, no binding 
could be detected (data not shown). The reported interaction though is between the 
membrane protein complex Patched-1-SHH-GAS (and possibly with SMO), but this 
interaction could not be tested, as we did not have resources to produce and purify 
Patched-1 or further related components. 
4.2.2 SOLUTION STRUCTURE, MALLS, CD, SPR 
 
The overall solution structure was evaluated by using SAXS (Bernado et al. 2007; 
Petoukhov et al. 2012; Konarev et al. 2003; Petoukhov & Svergun 2013) in 
combination with rigid body homology modelling of domains 
(http:raptorx.uchicago.edu/) (Bernadó & Svergun 2012; Svergun 1999). The structure 
?
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highly resembled the GFRα1 structure, but it had several flexible parts, a long flexible 
loop in domain 1 as mentioned earlier, and a linker region between domains 1 and 2. 
The region after domain 2 was very flexible and disordered (Figure 12). The protein 
was monomeric. The monomeric state of the protein in solution at a concentration of 
approximately 1 mg/ml was verified using SEC-MALLS, and also SAXS.  
 
 
 
 
 
Figure 12: A structural model of GAS1 by using SAXS and homology modelling. The alpha helical 
two domained structure (blue), modelled using GFRα domains as a template (for example, PDB 2VE5) 
(http:raptorx.uchicago.edu/). The green surface is the SAXS ab initio model of soluble GAS1 
(DAMMIF/DAMAVER) (Svergun 1999). The grey spheres are modelled, missing residues (Coral). 
The selected models had a Chi2  =0.84 fit to the measured data (further details in Study I). Size 
estimation for the model given in Ångströms (green arrows). Data from Study I, (Rosti et al. 2015) 
reproduced with permission from BMC Biochemistry. Copyright (2015) www.biomedcentral.com. 
 
Width ca. 60 Å
Lenght ca. 60 Å
Tail ca. 75 Å
Depth ca. 75 Å
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We used circular dichroism (CD) to confirm the overall folding and to estimate the 
disulphide bonding of the protein. We attempted to unfold the protein by temperature 
denaturation, but no significant melting point was detected. Most likely due to high 
disulphide content the protein was thermally very stable, and gave no clear result for 
a melting transition in CD measurements. Thermal stability could not be determined 
with ThermofluorTM, as the fluorescent dye most likely reacted with the protein 
immediately and no increase in fluorescence signal was observed, possibly due to its 
hydrophobic nature. 
4.2.3 CRYSTALLIZATION OF GAS1?
 
Crystallization was tried several times with protein concentrations from 1 to 10 mg/ml 
and with all the typical random screens used in the University of Helsinki core facility 
crystallization unit. The random screens used were, for example, Helsinki Random I, 
II, Factorial, Synergy, Cryo, and optimizations from these. 
The crystallization was tested at room temperature, and at +4 oC. Partial proteolysis 
by adding 1:200 or 1:500  (w/w)  α-chymotrypsin to cleave off the flexible parts did 
not enhance the crystallization (data not shown). Based on the sequence based 
prediction, the protein has only one N-glycosylation site. The protein was analysed in 
MS (Helsinki proteomics unit, Study I) and the results supported the prediction that 
GAS1 is not heavily glycosylated. The crystallization set-ups were done with both 
glycosylated (29.8 kDa)  and deglycosylated protein (28.9 kDa).  Most of the time the 
protein aggregated or formed spherulites (Figure 13). Few non-diffracting needles 
were formed.  
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In summary, attempts to crystallize GAS1 were usually not successful and when small 
needle-like crystals formed they did not diffract (Figure 13). 
 
 
 
 
 
 
Figure 13: GAS1 crystallization. The best hit was from 25% tert-Butanol and 100 mM Tris-HCl pH 
8,5 (left, needles). Most of the time only spherulites were formed. Here is one example: Helsinki 
Random II, 0.1 M Magnesium formate, 15 % PEG 3350 (right). 
 
To enhance the crystallization, I modified the construct to contain only domain1 (D1), 
or 1 and 2 (D1-2) (Figure 14A and B), but these constructs failed to express in the 
baculovirus system (Figure 14C). 
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Figure 14: GAS1 domains and expression trial of GAS1 D1-D2. From left: A) sequence based 
homology models of domains 1 (AA 40-150, bluegreen) and 2 (AA151-250, yellow/orange). B) The 
corresponding amino acid sequences of domains 1 and 2. C) Baculovirus expression trial of domain 1-
2, western blot against the FLAG-tag. Control protein shows clear expression, where as GAS1 does not 
express. Arrow indicating a faint band, detected from the cell pellet. Expression and western blot 
analysis was performed at the Tampere Proteomics unit.  
4.3 ENGINEERED LRRTM2 AND SALM1-5 (STUDIES II AND 
III) 
4.3.1 PRODUCTION OF ENGINEERED LRRTM2 AND BINDING TRIALS 
?
The LRRTM2 protein sequence was modified in order to make it more 
thermostable based on consensus sequence design, as done successfully previously on 
other repeat proteins (Binz et al. 2003; Main et al. 2003). The amino acids for the 
40 L AHGRRLICWQ ALLQCQGEPE CSYAYNQYAE ACAPVLAQHG GGDAPGAAAA AFPASAASFS SRWRCPSHCI SALIQLNHTR 
RGPALEDCDC AQDENCKSTK RAIEPCLPRT-150 STOP
151- SGGGAGGPGA GGVMGCTEAR RRCDRDSRCN LALSRYLTYC GKVFNGLRCTDECRTVIEDM LAMPKAALLN 
DCVCDGLERP ICESVKENMA RLCFGAELGN - 250 STOP
A
MW     + ctrl D1-D2P D1-D2s
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presumed ligand binding region of the LRR domain concave surface were left intact 
as in the LRRTM2 sequence, and also the N- and C-terminal capping region were 
mostly unmodified (designed by Dr. Tommi Kajander). Other regions were replaced 
with the consensus sequence for the LRR repeats from the hagfish and lamprey 
variable lymphocyte receptor (VLR) proteins (Seiradake et al. 2014; Kajander et al. 
2011; Uvarov et al. 2014).  
The stabilizing elements enabled the crystallization of the engineered version of 
LRRTM2, and the structure could be solved (for details see Study II). 
The obtained structure (Figure 15) revealed the basic features of this protein family, 
and insight towards its function. Based on the structure and the engineered mutations 
and conservation we could model the neurexin binding.  
 
 
 
 
 
 
Figure 15: The Structure of the engineered LRRTM2 protein, with modelled N-glycan. Adapted 
with permission from Study II (Paatero et al. 2016) Copyright (2016) American Chemical Society. 
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The protein was produced by the baculovirus method in the Tampere BioMediTech 
proteomics unit (http://cofa.uta.fi/protein.html). Both the batch and the FPLC methods 
were used to optimize and purify the His-tagged engineered LRRTM2. The protein 
seemed to be stable in solution, and after the initial purification steps the unbound 
protein could be re-purified from the media. The pure engineered LLRTM2 protein 
was verified to be active and used in binding trials to β1-neurexin. The interaction was 
detected by ELISA assay (data not shown). The protein was used later on in a surface 
plasmon resonance assay to measure the affinity. The affinity of the modified protein 
was significantly lower, being micromolar (ca. 2.7 μM) and Ca2+ dependent, 
compared to the unmodified recombinant protein with (55-68 nM) nanomolar affinity 
(Study II). This alteration in binding could be caused by several factors, such as the 
difference in the curvature of the protein due to changes in sequence, or the lack of 
glycans affecting the conformation.  
 
The protein stayed functional also in cell based assays and could form synaptic 
contacts with neurexin (Study II). When the structure was solved I participated in the  
computational docking studies which was done in order to model the neurexin binding 
to LRRTM2 (de Vries et al. 2010). We managed to build a model for possible 
LRRTM2-NRXN interaction based on complex structure on Neuroligin-Neurexinβ 
(Study II). 
4.3.2 LRR PROTEIN PRODUCTION IN E. COLI 
?
For crystallization purposes we also tested the possibility of producing the 
extracellular eucaryotic LRR domains from  E.coli.  
Briefly, for prokaryotic expression trials parts of disulphide containing extracellular 
LRR proteins were cloned into different types of expression vectors such as modified 
pET23 MBP-vector, and pET32a thioredoxin- vector (Figure 16) (unpublished).  
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Figure 16: LRR E.coli expression constructs. The proteins of interest were cloned into: A) a pET23 
based vector, with an MBP-tag (orange) and a FactorXa cleavage site (red line) in the N-terminus B) a 
pET32a vector with a thioredoxin-tag (orange) and a FactorXa cleavage site (red line in the N-terminus 
C) and a pGEX6P-1 with a GST-tag (orange) and PreScission Protease site (red line). 
 
Initially the idea was to enhance the solubility of LRRs by pre-producing folding 
factors (Nguyen et al. 2011), protein disulfide isomerase (PDI) and an sulfhydryl 
oxidase, in the E.coli cytosol. Secondly, we tried to simultaneously produce our model 
protein AMIGO-1 using the same system. Since its ectodomain structure is known 
(Kajander et al. 2011), it would have been a good model protein for expression and 
characterization from E. coli. 
For these trials parts of LRRTM1 extracellular LLR-domain (amino acids 35-370) the 
whole extracellular domain of LLRTM1 (amino acids 35-427) and the AMIGO-1 LRR 
domain (amino acids 28-275) were cloned to listed vectors (Figure 16). In addition, 
the LRRTM1 C-terminal unstructured part (amino acids 365-427) was clone into a 
pGEX6P-1 vector containing the GST-tag and PreScission protease site.  
The main idea was to develop a protein production and purification system for the 
eukaryotic membrane LRR receptor proteins, with folding factors in E.coli. The 
prokaryotic system would allow for increased protein production levels that would 
enable us to produce higher amounts of protein for structural studies. The expression 
of the proteins with folding factors was done in collaboration with Prof. Lloyd 
Ruddock, University of Oulu, but LRR-proteins were not expressed in soluble form in 
reasonable amounts in E. coli  and were mostly found in inclusion bodies. Only 
???? ? ???? Sequence of interest Sequence of interestSequence of interest ???
pET23 pGEX6P-1pET32a
N NN
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construct where a very faint band could be detected was our control protein AMIGO1 
(amino acids 28-275) (data not shown).  
4.3.3 PRODUCTION OF SALM1 AND 5 FOR CRYSTALLIZATION TRIALS 
?
The expression of SALM 1 and SALM5 (III, manuscript) was also 
tested. I used the constructs of mouse SALM1 (residues 20-378), and SALM5 
(residues 20-504) for Drosophila S2 expression (Figure 17). 
 
 
 
 
 
Figure 17: SALM1 and 5 constructs used for expression trials in Drosophila S2 cells. From left: 
Salm1 construct (AA20-378) with LRR and IgC2, and Salm5 LRR-IgC2-FNIII domains were cloned 
into a pRMCD33-Fc expression vector (Bunch et al. 1988). Adapted from Study III (manuscript) 
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After several trials, I could stably transfect the available SALM1 (LRR-IgC2) and 
SALM5 (LRR-IgC2-FNIII) into Drosophila S2 cells and produce them using the 
Invitrogen Drosophila S2 protocol (Figure 18).  
 
 
?Figure 18: Western blot and protein A purification of Fc-tagged SALM1 and 
SALM5 protein from a Drosophila S2 stable cell line. A) Supernatant from the stable cell 
line was used to detect Fc-tagged protein by Western blot, and the LRRTM2 was used as a 
positive control. From left: 1-2) SALM1 3) Salm5 4) LRRTM2 5) plain Fc-tag used as control. 
B) The SALM1 protein expressed well and was purified using Protein A beads. Fractions from 
Protein A purified SALM1 are shown on an SDS-page gel. Adapted from Study III 
(manuscript). 
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The longer SALM5 LRR-IgC2-FNIII construct did not express in reasonable amounts, 
either in a stable cell line or in a transient expression system. However the shorter 
SALM1 LRR-IgC2expressed to usable amounts from stably transfected cells.  
The protein was predicted to be heavily glycosylated, and the effect of deglycosylation 
was tested by PNGaseF digestion (Figure 19). 
 
 
 
Figure 19: PNGaseF digestion of native SALM1 protein followed by SDS-page. 1) glycans intact, 
2) PNGaseF treated and deglycosylated SALM1 with diminished size, 3) empty lane, 4) non-
PNGaseF treated Salm1 (control), size markers. The additional approx. 30 kDa band is most likely the 
remains of the Fc-tag. 
 
The protein had a high tendency to dimerize, and possibly formed aggregates or 
oligomerized. A soluble fraction was purified for crystallization and MS-assay. 
Different crystal forms of SALM1 LRR-IgC2 are shown in Figure 20 (adapted from 
Study III, manuscript). 
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Figure 20: SALM1 crystals. The best crystals were mainly obtained using glycosylated protein at 7.2 
mg/ml concentration A) 0.1 M Bis-Tris pH 5.5, 1 M Ammonium sulphate, 1% PEG 3350 
(deglycosylated) produced only small crystals (white arrows). B) 35% Tacsimate pH 7.0, 
(deglycosylated), C-D) MgCl2, 0.1 M Hepes, pH 7.5, 22% w/v Poly (acrylic acid sodium salt) 5100. C) 
glycosylated protein, and D) seeding the deglycosylated protein sample with the seeds from 
glycosylated protein.  
We optimized the crystallization by several parameters (Table 2), and obtained 
diffraction quality crystals. Unfortunately, the best diffraction was only to 5 Å, and 
the structure could not be solved due to high anisotropy and low diffraction  quality. 
The crystallizations were repeated several times, which yielded more crystals, but 
none diffracted better. The data collection was continued with dehydration studies, but 
with this approach the diffraction was lost totally after the crystals had been 
dehydrated by 5% from 98% humidity, as screened by room temperature diffraction 
data analysis at ESRF with a humidity control device.  
 
 
 
 
? ?
? ?
??
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Table 2. Summary of the crystallization screens in chronological order done 
using robotics. Typically, the protein sample contained Tris 30 mM, NaCl 150 mM 
buffer. 
Screen name Feature Protein concentration Glycosylated 
Helsinki Random I Initial screen 4.5 mg/ml Yes 
Helsinki Random I Initial screen 10 mg/ml PNGaseF treated 
JSGC (see Fig. 5C) Initial screen 7 mg/ml Yes * 
Custom screen 
based on JSGC 
Optimization 
 
7.2 mg/ml Yes 
Custom screen 
based on JSGC Optimization  
7.2 mg/ml Yes 
Helsinki Cryo Initial screen 7 mg/ml Yes 
JSGC (see Fig. 5D) Optimization, Microseeding 5 mg/ml Yes * 
Midas Optimization Microseeding 5 mg/ml Yes 
Helsinki Cryo Optimization Microseeding 5 mg/ml Yes 
Helsinki Random II Optimization 5 mg/ml PNGaseF treated 
JSGC Optimization 5 mg/ml PNGaseF treated 
Results and discussion 
 
48 
JSCG based grid. Optimization ( two grids) 10 mg/ml Glycosylated 
Grid 
based on Helsinki    
Random II 
(see Fig.5 A and B) 
Optimization 9 mg/ml PNGaseF treated * 
 
*Initial hit condition JSGC (G2) (Molecular dimensions). After this, optimization by 
altering conditions, trying to optimize cryo-conditions, screen for new hit conditions 
such as Midas (Molecular dimensions), and to enhance crystallization by seeding. 
Also additives were tried (Hampton research). Helsinki Random II conditions (C4) 
35% Tacsimate pH 7.0, and (C8) 0.1 M Bis-Tris pH 5.5, 1 M Ammonium sulphate, 
1% PEG 3350 were also varied in custom screens. Helsinki screens from Helsinki 
crystallization unit. 
4.3.4 USING SALM1 AND LRRTM2 FOR LIGAND FISHING TRIALS 
 
The recombinant mouse SALM1 protein (LRR-IgC2) was tested for fishing new 
ligands from mouse brain lysate by using purified, recombinant SALM1 as bait. The 
trial was done in collaboration with Prof. Matti Airaksinen and Dr. Pavel Uvarov at 
the Neuroscience Center and Institute of Biomedicine, Faculty of Medicine. 
In our initial trials recombinant SALM1 did not bind any significant new ligands. 
However, we could confirm that the positive and negative controls worked as 
expected. 
When the results were analysed by the Viikki proteomics unit, it seemed that the best 
hits found on the MALDI-TOF mouse panel with recombinant mouse SALM1 used 
as bait gave the highest score for ligand to rat SALM1 (G3V7J3_RAT) (Figure 21), 
indicating that the recombinant protein formed interactions with natural SALM1 
proteins present in rat brain lysate (unpublished).  
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Figure 21: Graph describing the distribution and approximate amount level of peptides found in 
ligand screen. Best hit was to Leucine rich repeat and fibronectin type III domain containing, Rattus 
norvegicus, G3V7J3_RAT with score 590, when estimating peptide spectrum matches (PSMS). 
Smaller bars indicating other hits ranging from 131 to minimum 20 PSMS (from left to right). These 
were mostly tubulin, and endoplasmic reticulum chaperones such as Calnexin and heat-shock proteins, 
such as Heat shock protein 60 (Hsp60)?(unpublished data).?
 
 
Recombinant LRRTM2, which was used as a positive control, interacted with NXRN 
of the brain lysate, whereas none of these complexes formed with the Fc-bait. This 
supports the findings that at least SALM1 has an affinity to itself , which is presumably 
higher than to other possible, available ligands. However, this does not exclude the 
possibility that SALM1 might have as yet unknown ligands.  
Another regulatory function hypothesized (Wang & Wenthold 2009) is that the N-
terminal part of SALMs could possibly be cleaved and released into the synaptic cleft, 
thus altering the effect of SALM. We could also hypothesize that the oligomerization, 
occurring at higher concentrations of SALM1 in solution might indicate the effect on 
the (SALM1 in cis) cell membrane, and could also inhibit  SALM1 (in cis or trans) or 
have an effect on other SALMs.  This would be similar type of effect as recent report 
?
???
???
???
???
???
???
???
PSMS
Distribution
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for SALM4 (Lie et al. 2016). Further studies are needed on membrane bound SALM1 
in comparison with soluble SALM1 in order to understand the possible biological 
functional role of monomeric, dimeric or oligomerized SALM1. 
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5.?CONCLUSIONS AND FUTURE PROSPECTS 
The data described in this thesis show clearly that we are not limited only to one 
method for structural and functional characterization studies when working with 
challenging protein targets. More knowledge on neuronal proteins is needed to 
elucidate their biological interactions and the causes of the associated disorders, and 
these investigations benefit from combining different methods and research 
approaches  
In this thesis I have studied GAS1 and LRR proteins and their structural features. 
GAS1 is a multifunctional protein. The ability of soluble GAS1 to bind RET in a 
ligand independent manner is an interesting feature, but the biological context needs 
further clarification, as the affinity of GAS1 for RET is low. Binding of an additional 
ligand could possibly increase the affinity to RET. As the structure of GAS1 seemed 
to differ from that of GFRαs, e.g. GAS1 has a large loop region with unknown 
function in domain 1, and lacks the reported amino acids for GFL binding, a crystal 
structure of the protein would definitely help clarify the differences. While we were 
not able to obtain the crystal structure, other methods such as SAXS enabled us to 
model the structure of GAS1 in solution with flexible, freely moving regions, and to 
clarify the overall structural features.  
The results gained from our study of the engineered LRRTM2 could be used as the 
basis for developing more efficient strategies to crystallize difficult targets, such as 
GAS1, together with trials of recombinant unmodified protein. Attempts to produce 
domains of GAS1 separately failed, but by comparing the amino acid sequences to 
solved structures of GFRα1, possibly some of the flexible regions of GAS1, such as 
the loop region, could be excluded, or replaced by the corresponding amino acids from 
GFRα1. This modification would need rational designing, and careful analysis of 
sequences  by comparing the X-ray and our structural model. 
Overall parallel studies with modified and unmodified proteins would enhance our 
understanding not only of the structure, but also of the factors, such as the importance 
of subtle changes in conformation and stability and glycosylations for the correct 
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folding and function. The effect of modifications could be estimated in basic studies 
similar to those we used for engineered LRRTM2, such as ligand binding by surface 
plasmon resonance, or thermostability by ThermoFluorTM. The biological 
functionality of the protein can be further tested in cell based assays. The LRRTM2 
modification changed the biophysical properties of the protein, making it more 
thermostable as predicted, eliminating the oligomerization tendency and making the 
affinity to NRXN strictly Ca2+ dependent. However, the protein remained biologically 
active, and was able to make synaptic contacts in cell culture, which indicates that the 
basic function was preserved. 
Our combined data of engineered LRRTM’s structure and binding to NRXN will 
enable small molecules to be docked to the structure in order to screen for inhibitors 
that could be used to start new cell based trials to verify the effect on the LRRTM2–
NRXN interaction. This would aid our understanding of the related disorders by 
helping us to decipher how the synaptic connections form, and how they are inhibited.  
My results with another LRR protein, SALM1, were very promising. The protein was 
unmodified, yet it crystallized well, even with glycans intact. Unfortunately, we could 
not obtain good quality diffraction data. SAXS analysis was also tried several times, 
but unlike with GAS1, the soluble SALM1 seemed to have a strong dimerization or 
oligomerization feature, which made the SAXS measurements nearly impossible. 
SALM1 seemed to be fairly stable, and to stay as a dimer in solution or form larger 
oligomers. This could imply that the oligomerization has some other important 
functions. However, the details of the biological function of SALM1 are unknown, 
and whether these oligomers have some functional relevance would require further 
investigation. 
Our results show the progress made towards resolving the structural features of these 
three proteins, which has brought us few steps closer to understanding their biological 
functions. Although I could not obtain an X-ray structure from GAS1 and SALMs, we 
were able to obtain the first, biologically active, engineered LRRTM2 structure and 
gained some understanding of the structural features of GAS1 and SALM1. Our 
efforts on the construct modifications and structure solutions of GAS1, LRRTM2, and 
SALM1 could be used as a basis to engineer, and investigate difficult target proteins 
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in general. X-ray crystallography is a demanding method, and often requires 
considerable optimization before a structure can be solved or the protein crystallized. 
Beyond the characterizations presented in this thesis on the structure, folding and 
ligand interactions, one cannot exclude the effect of glycosylations on the interactions 
and folding of mammalian proteins. Another important open question is whether 
attachment of the protein to the membrane by, e.g. GPI-anchor or transmembrane part, 
changes its behaviour in vivo compared to its properties in solution. 
To conclude, the combined efforts of structural biologists, cell biologists, and 
neuroscientists are needed to understand the biology behind the complex biological 
function of the synaptic and other neuronal proteins. The studies described in this 
thesis have contributed to our understanding of three such proteins, GAS1, LRRTM2 
AND SALM1. 
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